Menu
Banner Image

Ella DeTrizioPartner

Ella DeTrizio


Partner
New Jersey
Email:  edetrizio@reitlerlaw.com
Phone:  609-514-1504

EXPERIENCE

Ella represents venture-backed emerging growth technology companies across the full-spectrum of their corporate activities, including formation, venture capital financings and other private placements, public offerings, 1934 Act reporting, acquisitions, and other general corporate matters. She also counsels funds on their investments in these emerging growth technology companies. Her clients have included venture-backed companies primarily in the biotechnology, biopharmaceutical and medical devices sectors, as well as other technology-based companies.

Representative Transactions

Venture Capital:

  • $30 million Series B Preferred Stock financing representing investors in a biologics company with products to address metastatic bladder cancer and achondroplasia (dwarfism).
  • $32 million Series B Preferred Stock financing representing investors in a cross-border investment in a genomic information company headquartered in Vancouver, British Columbia.
  • $50 million Series E Preferred Stock financing representing investors in a medical device company pioneering a catheter-based treatment for heart failure.
  • $45 million Series C Preferred Stock financing representing investors in a pharmaceutical company to support commercialization of FDA-approved drugs for hypertension and ADHD.
  • $28 million Series C Preferred Stock financing representing investors in a medical device company pioneering photodynamic orthopedic implants.
  • $12 million Series C Preferred Stock financing representing investors in a medical device company that makes a prosthesis used in hernia repairs.
  • $61 million initial public offering of a medical device company representing selling stockholders.
  • $55 million Series C Preferred Stock financing representing investors in a Canadian-based, clinical stage cardiovascular company for advancement of a product to address paroxysmal supraventricular tachycardia.
  • $7 million Series B Preferred Stock financing representing investors in a biotechnology Acute Myeloid Leukemia company developing treatments for (AML) and myelodysplastic Syndrome (MDS).

EDUCATION

  • Yale Law School, J.D. 1984
  • Rutgers University, B.A., Economics, summa cum laude
  • Phi Beta Kappa; Omicron Delta Epsilon, The International Honor Society for Economics; Alpha Phi Omega, a national co-ed service fraternity

PROFESSIONAL

  • Adjunct Professor
  • Rutgers Law School–Camden
  • Mar 2014 – Apr 2014 
  • Mar 2015 –  Apr 2015
  • Served as an adjunct professor at Rutgers Camden School of Law in the Spring terms of 2014 and 2015. Subjects included Business Planning and Structuring and negotiation venture capital financial transactions.

ADMISSIONS

  • New Jersey

Experience

Ella represents venture-backed emerging growth technology companies across the full-spectrum of their corporate activities, including formation, venture capital financings and other private placements, public offerings, 1934 Act reporting, acquisitions, and other general corporate matters. She also counsels funds on their investments in these emerging growth technology companies. Her clients have included venture-backed companies primarily in the biotechnology, biopharmaceutical and medical devices sectors, as well as other technology-based companies.

Representative Transactions

Venture Capital:

  • $30 million Series B Preferred Stock financing representing investors in a biologics company with products to address metastatic bladder cancer and achondroplasia (dwarfism).
  • $32 million Series B Preferred Stock financing representing investors in a cross-border investment in a genomic information company headquartered in Vancouver, British Columbia.
  • $50 million Series E Preferred Stock financing representing investors in a medical device company pioneering a catheter-based treatment for heart failure.
  • $45 million Series C Preferred Stock financing representing investors in a pharmaceutical company to support commercialization of FDA-approved drugs for hypertension and ADHD.
  • $28 million Series C Preferred Stock financing representing investors in a medical device company pioneering photodynamic orthopedic implants.
  • $12 million Series C Preferred Stock financing representing investors in a medical device company that makes a prosthesis used in hernia repairs.
  • $61 million initial public offering of a medical device company representing selling stockholders.
  • $55 million Series C Preferred Stock financing representing investors in a Canadian-based, clinical stage cardiovascular company for advancement of a product to address paroxysmal supraventricular tachycardia.
  • $7 million Series B Preferred Stock financing representing investors in a biotechnology Acute Myeloid Leukemia company developing treatments for (AML) and myelodysplastic Syndrome (MDS).
Read more

Education

  • Yale Law School, J.D. 1984
  • Rutgers University, B.A., Economics, summa cum laude
  • Phi Beta Kappa; Omicron Delta Epsilon, The International Honor Society for Economics; Alpha Phi Omega, a national co-ed service fraternity

Professional

  • Adjunct Professor
  • Rutgers Law School–Camden
  • Mar 2014 – Apr 2014 
  • Mar 2015 –  Apr 2015
  • Served as an adjunct professor at Rutgers Camden School of Law in the Spring terms of 2014 and 2015. Subjects included Business Planning and Structuring and negotiation venture capital financial transactions.

Admissions

  • New Jersey

Ella represents venture-backed emerging growth technology companies across the full-spectrum of their corporate activities, including formation, venture capital financings and other private placements, public offerings, 1934 Act reporting, acquisitions, and other general corporate matters. She also counsels funds on their investments in these emerging growth technology companies. Her clients have included venture-backed companies primarily in the biotechnology, biopharmaceutical and medical devices sectors, as well as other technology-based companies.

Read more

Representative Transactions

Venture Capital:

  • $30 million Series B Preferred Stock financing representing investors in a biologics company with products to address metastatic bladder cancer and achondroplasia (dwarfism).
  • $32 million Series B Preferred Stock financing representing investors in a cross-border investment in a genomic information company headquartered in Vancouver, British Columbia.
  • $50 million Series E Preferred Stock financing representing investors in a medical device company pioneering a catheter-based treatment for heart failure.
  • $45 million Series C Preferred Stock financing representing investors in a pharmaceutical company to support commercialization of FDA-approved drugs for hypertension and ADHD.
  • $28 million Series C Preferred Stock financing representing investors in a medical device company pioneering photodynamic orthopedic implants.
  • $12 million Series C Preferred Stock financing representing investors in a medical device company that makes a prosthesis used in hernia repairs.
  • $61 million initial public offering of a medical device company representing selling stockholders.
  • $55 million Series C Preferred Stock financing representing investors in a Canadian-based, clinical stage cardiovascular company for advancement of a product to address paroxysmal supraventricular tachycardia.
  • $7 million Series B Preferred Stock financing representing investors in a biotechnology Acute Myeloid Leukemia company developing treatments for (AML) and myelodysplastic Syndrome (MDS).
Read less
  • Yale Law School, J.D. 1984
  • Rutgers University, B.A., Economics, summa cum laude
  • Phi Beta Kappa; Omicron Delta Epsilon, The International Honor Society for Economics; Alpha Phi Omega, a national co-ed service fraternity
Read more

Representative Transactions

Venture Capital:

  • $30 million Series B Preferred Stock financing representing investors in a biologics company with products to address metastatic bladder cancer and achondroplasia (dwarfism).
  • $32 million Series B Preferred Stock financing representing investors in a cross-border investment in a genomic information company headquartered in Vancouver, British Columbia.
  • $50 million Series E Preferred Stock financing representing investors in a medical device company pioneering a catheter-based treatment for heart failure.
  • $45 million Series C Preferred Stock financing representing investors in a pharmaceutical company to support commercialization of FDA-approved drugs for hypertension and ADHD.
  • $28 million Series C Preferred Stock financing representing investors in a medical device company pioneering photodynamic orthopedic implants.
  • $12 million Series C Preferred Stock financing representing investors in a medical device company that makes a prosthesis used in hernia repairs.
  • $61 million initial public offering of a medical device company representing selling stockholders.
  • $55 million Series C Preferred Stock financing representing investors in a Canadian-based, clinical stage cardiovascular company for advancement of a product to address paroxysmal supraventricular tachycardia.
  • $7 million Series B Preferred Stock financing representing investors in a biotechnology Acute Myeloid Leukemia company developing treatments for (AML) and myelodysplastic Syndrome (MDS).
Read less
  • Adjunct Professor
  • Rutgers Law School–Camden
  • Mar 2014 – Apr 2014 
  • Mar 2015 –  Apr 2015
  • Served as an adjunct professor at Rutgers Camden School of Law in the Spring terms of 2014 and 2015. Subjects included Business Planning and Structuring and negotiation venture capital financial transactions.
Read more

Representative Transactions

Venture Capital:

  • $30 million Series B Preferred Stock financing representing investors in a biologics company with products to address metastatic bladder cancer and achondroplasia (dwarfism).
  • $32 million Series B Preferred Stock financing representing investors in a cross-border investment in a genomic information company headquartered in Vancouver, British Columbia.
  • $50 million Series E Preferred Stock financing representing investors in a medical device company pioneering a catheter-based treatment for heart failure.
  • $45 million Series C Preferred Stock financing representing investors in a pharmaceutical company to support commercialization of FDA-approved drugs for hypertension and ADHD.
  • $28 million Series C Preferred Stock financing representing investors in a medical device company pioneering photodynamic orthopedic implants.
  • $12 million Series C Preferred Stock financing representing investors in a medical device company that makes a prosthesis used in hernia repairs.
  • $61 million initial public offering of a medical device company representing selling stockholders.
  • $55 million Series C Preferred Stock financing representing investors in a Canadian-based, clinical stage cardiovascular company for advancement of a product to address paroxysmal supraventricular tachycardia.
  • $7 million Series B Preferred Stock financing representing investors in a biotechnology Acute Myeloid Leukemia company developing treatments for (AML) and myelodysplastic Syndrome (MDS).
Read less
  • New Jersey
Read more

Representative Transactions

Venture Capital:

  • $30 million Series B Preferred Stock financing representing investors in a biologics company with products to address metastatic bladder cancer and achondroplasia (dwarfism).
  • $32 million Series B Preferred Stock financing representing investors in a cross-border investment in a genomic information company headquartered in Vancouver, British Columbia.
  • $50 million Series E Preferred Stock financing representing investors in a medical device company pioneering a catheter-based treatment for heart failure.
  • $45 million Series C Preferred Stock financing representing investors in a pharmaceutical company to support commercialization of FDA-approved drugs for hypertension and ADHD.
  • $28 million Series C Preferred Stock financing representing investors in a medical device company pioneering photodynamic orthopedic implants.
  • $12 million Series C Preferred Stock financing representing investors in a medical device company that makes a prosthesis used in hernia repairs.
  • $61 million initial public offering of a medical device company representing selling stockholders.
  • $55 million Series C Preferred Stock financing representing investors in a Canadian-based, clinical stage cardiovascular company for advancement of a product to address paroxysmal supraventricular tachycardia.
  • $7 million Series B Preferred Stock financing representing investors in a biotechnology Acute Myeloid Leukemia company developing treatments for (AML) and myelodysplastic Syndrome (MDS).
Read less
Practices